ADVM

Adverum Biotechnologies (ADVM)

Adverum Biotechnologies Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ADVM

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/10	05 : 13	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ADVM	Adverum Biotechnologies Inc
2024/05/10	05 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ADVM	Adverum Biotechnologies Inc
2024/05/10	05 : 05	GlobeNewswire Inc.	Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights	NASDAQ:ADVM	Adverum Biotechnologies Inc
2024/05/03	21 : 00	GlobeNewswire Inc.	Adverum Biotechnologies to Participate in Upcoming May Investor Conferences	NASDAQ:ADVM	Adverum Biotechnologies Inc
2024/04/26	05 : 05	GlobeNewswire Inc.	Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting	NASDAQ:ADVM	Adverum Biotechnologies Inc
2024/03/19	05 : 05	GlobeNewswire Inc.	Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates	NASDAQ:ADVM	Adverum Biotechnologies Inc
2024/03/05	06 : 40	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:ADVM	Adverum Biotechnologies Inc
2024/02/29	06 : 05	GlobeNewswire Inc.	Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference	NASDAQ:ADVM	Adverum Biotechnologies Inc
2024/02/23	05 : 47	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:ADVM	Adverum Biotechnologies Inc
2024/02/22	05 : 39	Edgar (US Regulatory)	Form D - Notice of Exempt Offering of Securities	NASDAQ:ADVM	Adverum Biotechnologies Inc
2024/02/16	06 : 17	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:ADVM	Adverum Biotechnologies Inc
2024/02/15	10 : 26	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:ADVM	Adverum Biotechnologies Inc
2024/02/15	06 : 33	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ADVM	Adverum Biotechnologies Inc
2024/02/15	06 : 30	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:ADVM	Adverum Biotechnologies Inc
2024/02/15	06 : 27	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ADVM	Adverum Biotechnologies Inc
2024/02/15	06 : 05	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:ADVM	Adverum Biotechnologies Inc
2024/02/12	22 : 00	GlobeNewswire Inc.	Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference	NASDAQ:ADVM	Adverum Biotechnologies Inc
2024/02/10	07 : 50	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ADVM	Adverum Biotechnologies Inc
2024/02/10	01 : 41	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:ADVM	Adverum Biotechnologies Inc
2024/02/08	22 : 45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ADVM	Adverum Biotechnologies Inc
2024/02/08	21 : 00	GlobeNewswire Inc.	Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD	NASDAQ:ADVM	Adverum Biotechnologies Inc
2024/02/07	06 : 47	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ADVM	Adverum Biotechnologies Inc
2024/02/06	07 : 03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ADVM	Adverum Biotechnologies Inc
2024/02/05	21 : 45	GlobeNewswire Inc.	Adverum Biotechnologies Announces $127.5 Million Private Placement Financing	NASDAQ:ADVM	Adverum Biotechnologies Inc
2024/02/02	07 : 30	GlobeNewswire Inc.	Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024	NASDAQ:ADVM	Adverum Biotechnologies Inc
2024/01/29	22 : 00	GlobeNewswire Inc.	Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer	NASDAQ:ADVM	Adverum Biotechnologies Inc
2023/12/09	06 : 11	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ADVM	Adverum Biotechnologies Inc
2023/12/08	06 : 05	GlobeNewswire Inc.	Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society	NASDAQ:ADVM	Adverum Biotechnologies Inc
2023/12/05	06 : 09	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:ADVM	Adverum Biotechnologies Inc
2023/11/29	06 : 05	GlobeNewswire Inc.	Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference	NASDAQ:ADVM	Adverum Biotechnologies Inc